Want to see ARMP full AI Analyst Report?
ARMP Stock Chart & Stats
$5.56
$0.06(1.29%)
At close: 4:00 PM EDT
$5.56
$0.06(1.29%)
Day’s Range― - ―
52-Week Range$2.76 - $16.34
Previous CloseN/A
Volume56.99K
Average Volume (3M)99.91K
Market Cap
$217.14M
Enterprise Value$692.03
Total Cash (Recent Filing)$23.95M
Total Debt (Recent Filing)$313.95M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Nov 18, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.30
Shares Outstanding37,181,980
10 Day Avg. Volume87,283
30 Day Avg. Volume99,914
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.04
Price to Sales (P/S)46.41
P/FCF Ratio-8.65
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.50Price Target Upside214.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.62
Revenue Forecast (FY)$3.00M
Bulls Say, Bears Say
Bulls Say
Targeted Phage PlatformArmata’s focused phage platform addresses difficult bacterial infections, including antibiotic-resistant pathogens, where targeted treatment approaches may have significant medical need. This creates a durable strategic rationale for continued development and potential differentiation if clinical and regulatory milestones are achieved.
AP-SA02 Phase 3 ReadinessProgress across protocol submission, FDA feedback, and cGMP manufacturing reduces execution uncertainty ahead of the planned pivotal trial. Advancing these activities in parallel strengthens the lead program’s development position and improves the company’s path toward potential registration.
Non-dilutive Program FundingMeaningful non-dilutive DoD support helps finance AP-SA02 development while reducing reliance on immediate equity issuance for those activities. Continued federal backing also reinforces the strategic importance of Armata’s phage approach to antimicrobial resistance.
Bears Say
No Commercial Revenue BaseBecause Armata’s candidates are not yet approved commercial products, the company lacks a recurring product-revenue base to fund operations. Near-term financial progress therefore depends on development success, partnerships, or additional financing rather than established commercial demand.
Negative Equity And LeverageNegative equity and meaningful debt weaken financial flexibility and leave a limited balance-sheet cushion against continued operating losses. This structure can constrain capital allocation and increase financing risk as Armata funds late-stage trials and works toward potential commercialization.
Persistent Cash BurnSustained negative operating and free cash flow shows that the business is consuming capital rather than self-funding research and clinical operations. Continued cash burn makes external funding important and could limit development flexibility if financing conditions or investor support weaken.
Armata Pharmaceuticals News
ARMP FAQ
What was Armata Pharmaceuticals Inc’s price range in the past 12 months?
Armata Pharmaceuticals Inc lowest stock price was $2.76 and its highest was $16.34 in the past 12 months.
What is Armata Pharmaceuticals Inc’s market cap?
Armata Pharmaceuticals Inc’s market cap is $217.14M.
When is Armata Pharmaceuticals Inc’s upcoming earnings report date?
Armata Pharmaceuticals Inc’s upcoming earnings report date is Nov 18, 2026 which is in 73 days.
How were Armata Pharmaceuticals Inc’s earnings last quarter?
Armata Pharmaceuticals Inc released its earnings results on Aug 12, 2026. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.445 by $0.175.
Is Armata Pharmaceuticals Inc overvalued?
According to Wall Street analysts Armata Pharmaceuticals Inc’s price is currently Undervalued.
Does Armata Pharmaceuticals Inc pay dividends?
Armata Pharmaceuticals Inc does not currently pay dividends.
What is Armata Pharmaceuticals Inc’s EPS estimate?
Armata Pharmaceuticals Inc’s EPS estimate is -0.56.
How many shares outstanding does Armata Pharmaceuticals Inc have?
Armata Pharmaceuticals Inc has 37,181,980 shares outstanding.
What happened to Armata Pharmaceuticals Inc’s price movement after its last earnings report?
Armata Pharmaceuticals Inc reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.445. Following the earnings report the stock price went up 11.833%.
Which hedge fund is a major shareholder of Armata Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ARMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Armata Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (214.75% Upside)
$17.50 (214.75% Upside)
Blogger Sentiment
Bearish
ARMP Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
96.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.34%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
ARMP Stock 12 Month Forecast
Average Price Target
$17.50
▲(214.75% Upside)
Technical Analysis
Ownership Overview
0.60% Insiders
1.34% Mutual Funds
6.81% Other Institutional Investors
88.68% Public Companies and
Individual Investors